Scarica l'app Stockscreener
68.50
0.22%
-0.15
Arcellx Inc Borsa (ACLX) Ultime notizie
Can Arcellx Inc. deliver consistent dividends2025 Big Picture & Low Drawdown Investment Ideas - mfd.ru
Arcellx (NASDAQ:ACLX) Stock Rating Lowered by Rothschild & Co Redburn - MarketBeat
Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns By Investing.com - Investing.com South Africa
Rothschild Redburn downgrades Arcellx stock to Neutral on competition concerns - Investing.com India
FMR LLC Reduces Stake in Arcellx Inc: A Strategic Portfolio Adju - GuruFocus
(ACLX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Federated Hermes Inc. Cuts Position in Arcellx, Inc. $ACLX - MarketBeat
Arcellx stock maintains Buy rating at Stifel on promising safety data By Investing.com - Investing.com South Africa
Arcellx stock maintains Buy rating at Stifel on promising safety data - Investing.com Canada
Weekly Earnings: Is Cytokinetics Incorporated stock a good pick for beginnersInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
Arcellx Director Sells 6,000 Shares for $450,000 - AOL.com
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Does D-Domain CAR T Safety Data at Tandem 2026 Change The Bull Case For Arcellx (ACLX)? - simplywall.st
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Arcellx Inc (ACLX) and Align Tech (ALGN) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Align Tech (ALGN) and M3 (OtherMTHRF) - The Globe and Mail
Arcellx: Differentiated D-Domain BCMA CAR-T Profile and Safety Advantages Underpin Buy Rating and 58% Upside Potential - TipRanks
Arcellx (NASDAQ:ACLX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Arcellx (ACLX): Needham Reiterates Buy Rating, Price Target at $105 | ACLX Stock News - GuruFocus
Arcellx reports D-Domain binder shows no tonic signaling in CAR T therapy - Investing.com Australia
Arcellx, Inc. Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder - marketscreener.com
Arcellx's Novel D-Domain Binder Accepted for Presentation at 2026 Tandem Meetings - Intellectia AI
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder - marketscreener.com
Arcellx lab study flags dual VHH off-target hits, D-Domain stays quiet - Stock Titan
Arcellx's (ACLX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Pathway Capital Management LP Takes $4.19 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Assessing Arcellx (ACLX) Valuation After Recent Share Price Swings And Conflicting P/B And DCF Signals - Yahoo Finance
Is Arcellx (ACLX) Still Attractively Priced After Strong Multi Year Share Price Gains - Yahoo Finance
Y Intercept Hong Kong Ltd Takes $1.27 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Director David Lubner Sells 6,000 Shares of Arcellx Stock - Intellectia AI
Liquidity Mapping Around (ACLX) Price Events - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX) - The Globe and Mail
Portfolio Shifts: What is Arcellx Incs valuation compared to sectorMarket Weekly Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect - Finviz
UBS initiates coverage of Arcellx with bullish outlook as biotech fundamentals inflect - MSN
11 Best High Short Interest Stocks With Biggest Upside Potential - Insider Monkey
Quarterly Risk: Can Arcellx Inc maintain sales growthQuarterly Profit Review & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Bond Watch: Can Arcellx Inc be the next market leaderJuly 2025 Sector Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Arcellx to present anito-cel data at 2026 Tandem Meetings By Investing.com - Investing.com Australia
Guggenheim Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $120 - 富途资讯
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Legend Biotech, Arcellx rise after FDA draft guidance on multiple myeloma trials - MSN
Arcellx to present anito-cel data at 2026 Tandem Meetings - Investing.com
Arcellx study: earlier CAR T cut 5-year death risk by 48% - Stock Titan
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Arcellx Stock Is Sliding Despite Future Hopes - TipRanks
Arcellx director Lubner sells $450k in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx director Lubner sells $450k in ACLX stock - Investing.com
Why (ACLX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):